In this issue:
Leukaemia selection
Consolidation HDAC over 3 vs. 5 days in AML
Azacitidine and venetoclax in previously untreated AML
‘AAA’ maintenance after first CR in APL
Early FCR vs. watch and wait in stage Binet A high-risk CLL
BTK inhibitors effective in venetoclax-resistant CLL
Lymphoma selection
BR induction in transplanteligible and -ineligible patients with MCL
Survival in PCNSL/SCNSL after high-dose chemotherapy and autologous SCT with conditioning
Folinic acid rescue timing after high-dose methotrexate in non-Hodgkin’s lymphoma
Please login below to download this issue (PDF)